Physician
Watauga Pathology Associates PC
Watauga Pathology Associates PC was paid $3.36M by Medicaid between Jan 2018 and Dec 2024, across 189 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 34% of everything it billed.
33Billing provider infoWATAUGA PATHOLOGY ASSOCIATES PC
JOHNSON CITY, TN 37604
JOHNSON CITY, TN 37604
33aNPI1720053945assigned 02/21/2006
33bProvider typeCytopathology Physician
28Total paid$3.36M
24GClaims632,792
24DCodes billed189
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cytopathology Physician providers in Tennessee
Rank by total paid#1 of 6
Median peer was paid$64K
This provider vs. median53×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,520 | $189K | |
| 2019 | 90,647 | $352K | |
| 2020 | 36,739 | $246K | |
| 2021 | 34,817 | $314K | |
| 2022 | 66,565 | $425K | |
| 2023 | 116,517 | $538K | |
| 2024incomplete | 276,987 | $1.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 34% | 37,001 | 27,061 | $1.16M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 17% | 11,053 | 9,660 | $575K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 12% | 3,182 | 2,536 | $419K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 10% | 22,339 | 19,195 | $340K |
| 88307 | 8.6% | 5,629 | 4,887 | $287K | |
| 80053 | Comprehensive metabolic panel | 1.9% | 65,022 | 47,424 | $65K |
| 88304 | 1.5% | 5,678 | 4,897 | $52K | |
| 88312 | 1.5% | 2,920 | 2,508 | $49K | |
| 88342 | 1.4% | 2,106 | 1,555 | $47K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 598 | 586 | $32K |
| 87631 | <1% | 426 | 410 | $26K | |
| 88112 | <1% | 1,574 | 1,223 | $24K |
177 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 76,745 | $21K |
| 88141 | <1% | 1,364 | $19K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28,074 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18,737 | $17K |
| 88300 | <1% | 2,037 | $15K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 395 | $14K |
| 88142 | <1% | 916 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,513 | $10K |
| 84165 | <1% | 2,418 | $9K | |
| 84484 | <1% | 14,169 | $9K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 388 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,622 | $8K |
| 81001 | <1% | 24,792 | $7K | |
| 88341 | <1% | 228 | $6K | |
| 85060 | <1% | 1,067 | $6K | |
| 83735 | <1% | 20,790 | $6K | |
| 86334 | <1% | 1,230 | $5K | |
| 82803 | <1% | 5,853 | $5K | |
| 80061 | Lipid panel | <1% | 8,139 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,005 | $4K |
| 87040 | <1% | 6,812 | $4K | |
| 85027 | <1% | 19,479 | $4K | |
| 83605 | <1% | 7,740 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,338 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,334 | $4K |
| 83690 | <1% | 12,544 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,293 | $3K |
| 80074 | <1% | 653 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,069 | $3K |
| 84439 | <1% | 6,032 | $3K | |
| 82607 | <1% | 4,486 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,568 | $2K |
| 80320 | <1% | 3,952 | $2K | |
| 84100 | <1% | 10,346 | $2K | |
| 87077 | <1% | 5,924 | $2K | |
| 86803 | <1% | 1,135 | $2K | |
| 83880 | <1% | 4,345 | $2K | |
| 82728 | <1% | 2,714 | $2K | |
| 87186 | <1% | 4,278 | $2K | |
| 81329 | <1% | 653 | $1K | |
| 84703 | <1% | 4,900 | $1K | |
| 88302 | <1% | 213 | $1K | |
| 86901 | <1% | 7,705 | $1K | |
| 87081 | <1% | 1,268 | $992.73 | |
| 82746 | <1% | 1,694 | $953.42 | |
| 86140 | <1% | 4,659 | $936.04 | |
| 88313 | <1% | 44 | $917.84 | |
| 83540 | <1% | 2,639 | $905.93 | |
| 81003 | <1% | 9,922 | $865.31 | |
| 85610 | <1% | 6,420 | $855.46 | |
| 84702 | <1% | 1,731 | $808.16 | |
| 85652 | <1% | 2,271 | $721.31 | |
| 82140 | <1% | 1,172 | $704.98 | |
| 87070 | <1% | 2,658 | $649.44 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 215 | $642.38 |
| 88189 | <1% | 16 | $588.26 | |
| 82570 | <1% | 2,069 | $536.41 | |
| 84403 | <1% | 415 | $535.44 | |
| 83615 | <1% | 3,083 | $517.41 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,582 | $480.00 |
| 86900 | <1% | 7,838 | $445.93 | |
| 82670 | <1% | 190 | $444.83 | |
| 84146 | <1% | 261 | $437.38 | |
| 80055 | <1% | 212 | $432.80 | |
| 82784 | <1% | 501 | $432.35 | |
| 83001 | <1% | 207 | $419.08 | |
| 81025 | <1% | 8,296 | $418.43 | |
| 86850 | <1% | 5,880 | $410.35 | |
| 83789 | <1% | 1,236 | $400.60 | |
| 85379 | <1% | 1,713 | $385.83 | |
| 87340 | <1% | 532 | $357.54 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,798 | $343.16 |
| 87205 | <1% | 2,297 | $337.72 | |
| 83002 | <1% | 239 | $337.02 | |
| 85730 | <1% | 2,700 | $300.82 | |
| 83498 | <1% | 1,315 | $245.76 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,261 | $232.99 |
| 84550 | <1% | 1,768 | $216.00 | |
| 86077 | <1% | 12 | $208.04 | |
| 86592 | <1% | 1,455 | $207.10 | |
| 87507 | <1% | 59 | $199.00 | |
| 83520 | <1% | 1,295 | $186.20 | |
| 84481 | <1% | 398 | $185.18 | |
| 82043 | <1% | 880 | $182.86 | |
| 86141 | <1% | 487 | $166.67 | |
| 82533 | <1% | 411 | $163.54 | |
| 80202 | <1% | 1,097 | $162.07 | |
| 0352U | <1% | 32 | $155.20 | |
| 83021 | <1% | 1,274 | $150.41 | |
| 82248 | <1% | 560 | $148.77 | |
| 82542 | <1% | 656 | $140.63 | |
| 86923 | <1% | 487 | $135.28 | |
| 80076 | <1% | 2,702 | $132.77 | |
| 82247 | <1% | 2,079 | $130.52 | |
| 82550 | <1% | 808 | $130.35 | |
| 82261 | <1% | 1,235 | $116.31 | |
| 82105 | <1% | 188 | $113.12 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 111 | $107.76 |
| 83550 | <1% | 1,363 | $106.46 | |
| 86704 | <1% | 54 | $88.48 | |
| 82760 | <1% | 1,235 | $86.07 | |
| 84478 | <1% | 1,740 | $77.16 | |
| 87653 | <1% | 156 | $72.98 | |
| 87641 | <1% | 601 | $72.98 | |
| 82657 | <1% | 39 | $65.70 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 1,239 | $58.02 |
| 84153 | <1% | 123 | $57.93 | |
| 85014 | <1% | 1,329 | $55.62 | |
| 85018 | <1% | 1,426 | $53.24 | |
| 86038 | <1% | 124 | $51.80 | |
| 85007 | <1% | 1,067 | $51.74 | |
| 83525 | <1% | 195 | $49.92 | |
| 82330 | <1% | 340 | $46.91 | |
| 86762 | <1% | 56 | $36.48 | |
| 87522 | Neg quan hep c or qual rna | <1% | 148 | $34.43 |
| 85651 | <1% | 290 | $33.41 | |
| 80047 | <1% | 1,149 | $31.14 | |
| 82950 | <1% | 307 | $28.30 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 572 | $27.20 |
| 86880 | <1% | 645 | $23.45 | |
| 82565 | <1% | 431 | $22.53 | |
| 87210 | <1% | 288 | $21.13 | |
| 87015 | <1% | 112 | $20.26 | |
| 80177 | <1% | 12 | $18.78 | |
| 84155 | <1% | 1,138 | $18.58 | |
| 82024 | <1% | 15 | $17.35 | |
| 86706 | <1% | 56 | $15.65 | |
| 82009 | <1% | 127 | $15.24 | |
| 87449 | <1% | 156 | $14.55 | |
| 82977 | <1% | 266 | $12.64 | |
| 83970 | <1% | 109 | $10.13 | |
| 85045 | <1% | 687 | $9.67 | |
| 84132 | <1% | 172 | $8.22 | |
| 84295 | <1% | 154 | $6.33 | |
| 82947 | <1% | 144 | $5.43 | |
| 80143 | <1% | 1,808 | $4.72 | |
| 85520 | <1% | 177 | $4.62 | |
| 80179 | <1% | 1,753 | $3.14 | |
| 82150 | <1% | 29 | $2.94 | |
| 86431 | <1% | 43 | $2.50 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 1,442 | $0.00 |
| 84112 | 0% | 123 | $0.00 | |
| 84145 | 0% | 165 | $0.00 | |
| 80364 | 0% | 43 | $0.00 | |
| 84156 | 0% | 807 | $0.00 | |
| 83655 | 0% | 57 | $0.00 | |
| 84466 | 0% | 204 | $0.00 | |
| 87338 | 0% | 12 | $0.00 | |
| 82272 | 0% | 155 | $0.00 | |
| 87427 | 0% | 39 | $0.00 | |
| 80164 | 0% | 49 | $0.00 | |
| 87045 | 0% | 38 | $0.00 | |
| 80347 | 0% | 43 | $0.00 | |
| 80355 | 0% | 43 | $0.00 | |
| 80326 | 0% | 43 | $0.00 | |
| 83721 | 0% | 12 | $0.00 | |
| 87076 | 0% | 52 | $0.00 | |
| 86003 | 0% | 24 | $0.00 | |
| 82785 | 0% | 14 | $0.00 | |
| 84681 | 0% | 14 | $0.00 | |
| 87088 | 0% | 1,637 | $0.00 | |
| 82270 | 0% | 57 | $0.00 | |
| 82378 | 0% | 31 | $0.00 | |
| 86364 | 0% | 283 | $0.00 | |
| 87147 | 0% | 134 | $0.00 | |
| 80349 | 0% | 77 | $0.00 | |
| 86308 | 0% | 25 | $0.00 | |
| 83993 | 0% | 38 | $0.00 | |
| 80329 | 0% | 230 | $0.00 | |
| 84402 | 0% | 13 | $0.00 | |
| 87625 | 0% | 18 | $0.00 | |
| 87807 | 0% | 13 | $0.00 | |
| 86376 | 0% | 12 | $0.00 | |
| 87154 | 0% | 57 | $0.00 | |
| 87046 | 0% | 38 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 12 | $0.00 |
| 86617 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSOIKE, DAVID (PRESIDENT)